A
Anne B. Cropp
Researcher at Pfizer
Publications - 23
Citations - 3768
Anne B. Cropp is an academic researcher from Pfizer. The author has contributed to research in topics: Amlodipine & Heart failure. The author has an hindex of 11, co-authored 23 publications receiving 3526 citations. Previous affiliations of Anne B. Cropp include Durham University.
Papers
More filters
Journal ArticleDOI
The Seattle Heart Failure Model Prediction of Survival in Heart Failure
Wayne C. Levy,Dariush Mozaffarian,David T. Linker,Santosh C. Sutradhar,Stefan D. Anker,Anne B. Cropp,Inder S. Anand,Aldo P. Maggioni,Paul B. J. Burton,Mark D. Sullivan,Bertram Pitt,Philip A. Poole-Wilson,Douglas L. Mann,Milton Packer +13 more
TL;DR: The Seattle Heart Failure Model provides an accurate estimate of 1-, 2-, and 3-year survival with the use of easily obtained clinical, pharmacological, device, and laboratory characteristics.
Journal ArticleDOI
Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure.
Milton Packer,Christopher M. O'Connor,Jalal K. Ghali,Milton L. Pressler,Peter E. Carson,Robert N. Belkin,Alan B. Miller,Gerald W. Neuberg,David J. Frid,John H. Wertheimer,Anne B. Cropp,David L. DeMets +11 more
TL;DR: A new calcium-channel blocker, amlodipine, did not increase cardiovascular morbidity or mortality in patients with severe chronic heart failure and the possibility that amlidipine prolongs survival in Patients with nonischemic dilated cardiomyopathy requires further study.
Journal ArticleDOI
Diuretic resistance predicts mortality in patients with advanced heart failure
Gerald W. Neuberg,Alan B. Miller,Christopher M. O'Connor,Robert N. Belkin,Peter E. Carson,Anne B. Cropp,David J. Frid,Regina G. Nye,Milton L. Pressler,John H. Wertheimer,Milton Packer +10 more
TL;DR: The independent association of high diuretic doses with mortality suggests that diUREtic resistance should be considered an indicator of prognosis in patients with chronic CHF.
Journal ArticleDOI
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
Christie M. Ballantyne,Christie M. Ballantyne,Joel M. Neutel,Anne B. Cropp,William T. Duggan,Ellen Q. Wang,David R. Plowchalk,Kevin Sweeney,Nitin Kaila,John Vincent,Harold E. Bays +10 more
TL;DR: In conclusion, bococizumab significantly reduced LDL-C across all doses despite dose reductions in many subjects, and the most efficacious bococzumab doses were 150 mg Q14 days and 300 mg Q28 days.
Journal ArticleDOI
Role of Cytokines in the Mechanism of Action of Amlodipine: The PRAISE Heart Failure Trial ☆
Emile R. Mohler,Leif C Sorensen,Jalal K. Ghali,Douglas D. Schocken,Park W. Willis,John A Bowers,Anne B. Cropp,Milton L. Pressler +7 more
TL;DR: The beneficial effect of amlodipine in CHF may be due to a reduction of cytokines such as IL-6, which is lower than normal levels seen in patients with congestive heart failure.